Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Frequently asked questions
What sector does Exicure, Inc (XCUR) operate in?
Exicure, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Exicure, Inc (XCUR) current stock price?
As of the latest data, Exicure, Inc stock price is $1.09, with a previous close of $1.08. Exicure, Inc gained $0.01 in the last trading session, representing a 0.93% increase.
What is Exicure, Inc (XCUR) current market capitalization?
Exicure, Inc market cap is approximately 7.14 million.
What is Exicure, Inc (XCUR) Earnings Per Share (EPS)?
The trailing EPS is -$1.28.
What is Exicure, Inc (XCUR) EBITDA?
Exicure, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.08 million.
Does Exicure, Inc (XCUR) pay dividends?
No. Exicure, Inc does not pay a dividend.
When is Exicure, Inc (XCUR) next earnings report?
Exicure, Inc is expected to release its next earnings report on September 30, 2026.
What is Exicure, Inc (XCUR) beta (volatility) score?
Exicure, Inc has a beta of 3.621, indicating very high volatility compared to the market.